BOSTON, MA — March 30, 2022 — Alcanza Clinical Research, a mission-focused clinical research site network, announces the acquisition of Coastal Carolina Research Center (CCRC), one of the largest independent multi-therapeutic research sites in the United States. Founded in 1997, CCRC serves Charleston, SC, and surrounding areas through its dedicated clinical research unit, soon expanding to over 15,000 square feet and currently employing over 60 research staff.
“The reputation for performance and specialization in vaccine development that CCRC brings to patients will be a strong addition to our capabilities,” said Carlos Orantes, CEO of Alcanza. “We look forward to working collaboratively with CCRC to leverage their best practices as we scale operations across our national site network.”
Nathan Morton, President of CCRC, says, “We are extremely excited about the opportunity to join Alcanza Clinical Research – the emerging leader in inclusive clinical research practices. We share their commitment to educating all patients about the benefits of clinical research and the importance of enrolling diverse patient populations in clinical trials to advance health equity. By joining Alcanza Clinical Research, we will expand our impact by leveraging their unified platform services.”
CCRC will operate as an independent site within the Alcanza Clinical Research network and retain its name. Nathan Morton remains as President of CCRC and will serve as Chief Commercial Officer for the Alcanza network.
About Alcanza Clinical Research
Alcanza Clinical Research is the next-generation site network established to support the most significant demands in our industry: diverse patient access, efficient enrollment performance, and clinical quality. It practices inclusive research that delivers education and a range of clinical trial opportunities to all people on their terms. Located in Massachusetts, Michigan, New Hampshire, and South Carolina, Alcanza specializes in conditions across psychiatry, neurology, dermatology, and infectious disease therapeutic areas.